Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
- Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
- Japan to Boost Number of HPV Vaccination Base Hospitals
September 9, 2022
- What Is Seen as New Omicron Variant Detected in Japan: NIID
September 9, 2022
- LDP Group Urges Thorough Discussions on New Data for Shionogi COVID Pill Once Out
September 8, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
- Ultrasound Dementia Therapy Machine in Line for First Sakigake Device Designation, Japan Submission Eyed in 2025
September 6, 2022
- MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- Tatsumi Kagaku Faces Biz Improvement Order over Discrepant Manufacturing Method, Falsified Records
September 5, 2022
- METI Seeks 7 Billion Yen to Develop Next-Gen Drug Discovery Tech Platform: FY2023 Budget Request
September 5, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
September 5, 2022
- Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
- MHLW Council OKs Public Knowledge-Based Applications for FOLFOX Therapy for Stomach Cancer
September 2, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…